- £216.87bn
- £236.39bn
- $58.74bn
Press Digest: Wall Street Journal - October 26
Takeda to seek Japan approval for gastric cancer drug next year
AstraZeneca's stomach cancer drug extends overall survival, late-stage trial data finds (updated)
AstraZeneca's stomach cancer drug clears bar for extending overall survival in late-stage study
Brief: AstraZeneca - Perioperative Imfinzi® (Durvalumab) Plus Neoadjuvant Enfortumab Vedotin Reduced Risk Of Recurrence By 49% And Risk Of Death By 42% In Muscle-Invasive Bladder Cancer
Brief: Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer
Corrected: Amgen drug combined with immunotherapy extends survival in lung cancer trial
Brief: AstraZeneca Says ZEGFROVY 200 Mg Administered Orally Once Daily Now Available In US
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Abu Dhabi Biobank Partners With Astrazeneca To Advance Predictive Healthcare - AD Media Office
UK Stocks-Factors to watch on October 22 (updated)
Brief: AstraZeneca Says Ultomiris Approved In Us In IgAN
Ultomiris approved in US in IgAN
AstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Europe Research Roundup: Aumovio, Euronext, TotalEnergies